Your shopping cart is currently empty

BTX161 is a Thalidomide analogue. BTX161 is a potent CKIα degrader. In human AML cells, BTX161 mediates the CKIα degradation better than Lenalidomide as well as activates DNA damage response (DDR) and p53, and also stabilizes the p53 antagonist MDM2[1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,140 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $1,490 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,360 | 6-8 weeks | 6-8 weeks |
| Description | BTX161 is a Thalidomide analogue. BTX161 is a potent CKIα degrader. In human AML cells, BTX161 mediates the CKIα degradation better than Lenalidomide as well as activates DNA damage response (DDR) and p53, and also stabilizes the p53 antagonist MDM2[1]. |
| In vitro | BTX161 (25 μM; 4 hours; MV4-11 cells) enhances the expression of Wnt targets such as MYC without altering MDM2 mRNA levels [1]. At a concentration of 10 μM over 6 hours in MV4-11 cells, BTX161 independently increases p53 and MDM2 protein levels. When combined with THZ1, and especially with both THZ1 and CDK9, it further elevates p53 expression and maximizes caspase 3 activation [1]. |
| Molecular Weight | 272.3 |
| Formula | C15H16N2O3 |
| Cas No. | 2052301-24-1 |
| Smiles | Cc1cccc2C(=O)N(Cc12)[C@H]1CCCC(=O)NC1=O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.